NOVO-B.CO - Novo Nordisk A/S

Copenhagen - Copenhagen Real-time price. Currency in DKK
349.75
+5.15 (+1.49%)
As of 2:44PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close344.60
Open345.50
Bid349.70 x 0
Ask349.80 x 0
Day's range343.75 - 349.75
52-week range265.15 - 349.75
Volume741,003
Avg. volume2,247,563
Market cap828.708B
Beta (3Y monthly)1.44
PE ratio (TTM)22.35
EPS (TTM)15.65
Earnings dateN/A
Forward dividend & yield8.15 (2.37%)
Ex-dividend date2019-08-16
1y target est326.96
  • Reuters - UK Focus

    UPDATE 3-AstraZeneca diabetes drug shows promise in heart failure

    AstraZeneca made strides on Tuesday towards its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly. The British drugmaker said Farxiga was successful in reducing the risk of deadly heart attacks or disease progression in patients with a common form of heart failure in a clinical trial that could help win regulatory approval for its wider use.

  • Novo Nordisk contests Danish lawsuit claiming $1.75 billion
    Reuters

    Novo Nordisk contests Danish lawsuit claiming $1.75 billion

    Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement. "Novo Nordisk disagrees with the allegations and is prepared to defend the company in this matter," the company said. The securities lawsuit was filed by a number of shareholders who claims compensation worth a total of 11.785 billion Danish crowns (1.4 billion pounds) based on trading of Novo shares for two years from February 2015.

  • Novo Nordisk Waits for Its Next Launch
    Motley Fool

    Novo Nordisk Waits for Its Next Launch

    The second quarter wasn't too shabby either.

  • Novo Nordisk's new diabetes, obesity drugs lift sales outlook
    Reuters

    Novo Nordisk's new diabetes, obesity drugs lift sales outlook

    Novo Nordisk raised its sales forecast for this year thanks to growing demand for obesity drugs and a new injectable treatment for diabetes, now its growth engine as insulin sales decline. The Danish company is pinning its hopes on a relatively new treatment for type 2 diabetes as its older insulin drugs face political pressure over the soaring cost of the life-sustaining medicine in the United States. Sales of its new once-weekly injectable treatment, branded Ozempic, rose to 2.3 billion Danish crowns ($345 million) in the second quarter, which was higher than expected by analysts, sending shares in the world's top diabetes drugmaker 1.4% higher in early trading on Friday.

  • Reuters - UK Focus

    UPDATE 2-Italy leads European shares lower on political uncertainty

    European shares slid on Friday with Italian stocks 2.5% lower on political uncertainty, while comments by U.S. President Donald Trump that he was not going to make a trade deal with China also weighed on sentiment. Italy's main index touched a two month low with its bank index tumbling 4.5% after the leader of the ruling League party, Matteo Salvini, pulled his support for the country's governing coalition on Thursday and called for fresh elections.

  • Reuters - UK Focus

    Italy's political turmoil push European shares lower

    European shares fell on Friday, leading them to post a second straight week of losses, as worries about the stability of Italy's government rattled investors and concerns about Sino-U.S. trade tensions lingered. Milan's FTMIB index tumbled 1.6% with Italian banks hardest hit after the leader of the ruling League party, Matteo Salvini, pulled his support for the country's governing coalition on Thursday. Markets have recently been sensitive to political developments in Rome with Italian bond yields jumping each time there were doubts about the soundness of the government.

  • If You Had Bought Novo Nordisk (CPH:NOVO B) Stock Five Years Ago, You Could Pocket A 32% Gain Today
    Simply Wall St.

    If You Had Bought Novo Nordisk (CPH:NOVO B) Stock Five Years Ago, You Could Pocket A 32% Gain Today

    When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...

  • Diabetes drug maker Novo Nordisk buys pill factory in North Carolina
    Reuters

    Diabetes drug maker Novo Nordisk buys pill factory in North Carolina

    Novo Nordisk said on Tuesday it had bought a factory in North Carolina that would assist in manufacturing and packaging its new once-daily pill for treating type 2 diabetes. The tablet version of its diabetes drug, known as semaglutide, is an important growth prospect for the Danish drugmaker, which faces pressure on prices from competitors and U.S. lawmakers who have been critical of rising drug costs. Novo, the world's biggest producer of diabetes drugs, said the new plant near Durham would receive shipments of the active pharmaceutical ingredient needed to produce the pill from another factory under construction in North Carolina.

  • MarketWatch

    Sunnova Energy to offer 17.6 million shares in IPO, priced at $16 to $18 each

    Sunnova Energy International Inc. set terms for its planned initial public offering, saying in a regulatory filing it plans to offer 17.6 million shares priced at $16 to $18 each. The Houston-based solar energy company would raise $316.8 million at the top of that range. Seven banks are underwriting the deal, led by BofA Merrill Lynch, JPMorgan and Goldman Sachs. Proceeds will be used to pay down debt and for general corporate purposes.

  • Reuters - UK Focus

    UPDATE 2-Swiss stocks keep a lid on European shares as pharma drag lingers

    European shares were little changed on Friday as drugmakers came under pressure on worries the U.S. government may intervene over high drug prices, while Federal Reserve chairman Jerome Powell's dovish comments helped limit losses. The pan-European STOXX 600 index ended flat but broke a five-week winning streak as regional equities failed to take advantage of the Fed's accommodative stance this week. Swiss stocks underperformed, sliding more than 1% as drugmakers including Roche Holdings, Novartis and Novo Nordisk fell more than 2%.

  • Reuters - UK Focus

    LIVE MARKETS-Closing snapshot: Europe closes at 2-week low

    * European stocks fall after pharma stocks slide * STOXX 600 closes down 0.1%, healthcare stocks weigh: Siemens Healthineers -6% * Autos drag Germany's DAX 0.3% lower * UK housebuilders rise on upbeat survey * Indivior soars after lifting profit guidance, Reckitt rises after U.S. settlement Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: thyagaraju.adinarayan.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: EUROPE CLOSES AT 2-WEEK LOW (1601 GMT) Profit taking in pharma stocks has derailed the Powell-induced gains, pushing the STOXX 600 into the red in late afternoon trade and to its lowest close since June 28.

  • Reuters - UK Focus

    LIVE MARKETS-Health check for pharma as U.S. shifts focus to high drug prices

    * European stocks fall after pharma stocks slide * STOXX 600 down 0.2%, healthcare stocks weigh: Siemens Healthineers -7% * Autos drag Germany's DAX 0.3% lower * UK housebuilders rise on upbeat survey * Indivior soars after lifting profit guidance, Reckitt rises after U.S. settlement Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: thyagaraju.adinarayan.thomsonreuters.com@reuters.net HEALTH CHECK FOR PHARMA AS U.S. SHIFTS FOCUS TO HIGH DRUG PRICES (1527 GMT) European pharma stocks are taking a hit this afternoon on worries that U.S. Congress will now look at doing something about high drug prices.

  • Reuters - UK Focus

    UPDATE 2-European shares dip on pharma drag as Fed optimism sizzles out

    European shares closed at a two-week low on Thursday weighed down by pharma stocks on worries that U.S. government may intervene on high drug prices, while optimism from the Federal Reserve's dovish stance faded away. The pan-European stocks benchmark rallied earlier in the day on remarks from Fed Chair Jerome Powell but reversed course in late afternoon trading to close 0.1% lower. The White House announced that it was ditching its push for changes to the pharma rebate structure, providing some relief to health insurance companies but hurting drugmakers, including those in Europe.

  • Would Novo Nordisk A/S (CPH:NOVO B) Be Valuable To Income Investors?
    Simply Wall St.

    Would Novo Nordisk A/S (CPH:NOVO B) Be Valuable To Income Investors?

    Dividend paying stocks like Novo Nordisk A/S (CPH:NOVO B) tend to be popular with investors, and for good reason...

  • A Look at NVO’s Spending and Earnings in Fiscal 2019
    Market Realist

    A Look at NVO’s Spending and Earnings in Fiscal 2019

    In the first-quarter earnings investor presentation, Novo Nordisk (NVO) guided for YoY operating profit growth of 2% to 5%.

  • How NVO’s Revenues Are Trending in Fiscal 2019
    Market Realist

    How NVO’s Revenues Are Trending in Fiscal 2019

    Novo Nordisk (NVO) has guided for YoY revenue growth of 2% to 5% at a constant exchange rate in fiscal 2019.

  • What Analysts Recommend for GlaxoSmithKline and Novo Nordisk
    Market Realist

    What Analysts Recommend for GlaxoSmithKline and Novo Nordisk

    GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis.

  • The 10 Biggest Biotech Stocks
    Motley Fool

    The 10 Biggest Biotech Stocks

    Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.

  • GlobeNewswire

    Novo Nordisk A/S - Share repurchase programme

    Bagsværd, Denmark, 13 June 2019 - On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 ...

  • What Should Investors Know About Novo Nordisk A/S's (CPH:NOVO B) Growth?
    Simply Wall St.

    What Should Investors Know About Novo Nordisk A/S's (CPH:NOVO B) Growth?

    Since Novo Nordisk A/S (CPH:NOVO B) released its earnings in March 2019, analyst forecasts seem fairly subdued, as a...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes